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ABSTRACT
Background
Improved treatment has increased the life expectancy of patients with non-Hodgkin’s lym-
phoma, but few studies have addressed the issue of second cancer in patients treated for dif-
fuse large B-cell lymphoma. The aims of this study were to determine the incidence and time
free of second cancers in this subset of patients.
Design and Methods
We evaluated a cohort of 1280 patients with diffuse large B-cell lymphoma who were first treat-
ed between 1988 and 2003. We utilized the central database of the Gruppo Italiano Studio
Linfomi, which includes data on demographics, clinical characteristics, laboratory parameters,
treatment and follow-up of all patients with non-Hodgkin’s lymphoma enrolled in clinical trials.
Results
After a median follow-up of 51 months, 48 patients had developed a second cancer: 13 hema-
tologic malignancies and 35 solid tumors. The overall standardized incidence ratio in our cohort
(with a median age of 58 years) matched that of the general Italian population. The incidence
ratio of second tumors was age related, and the age groups 20-39 and 40-59 years showed
an increased risk. Overall, the cumulative incidence of second cancer was 8.2% at 15 years. A
multivariate analysis showed that older age at the time of diagnosis of lymphoma had a nega-
tive influence on the time free of second tumors.
Conclusions
In our cohort, only young patients showed an increased incidence ratio of second malignan-
cies, while the incidence ratio in patients aged over 59 years matched the incidence in the
Italian general population. Demographics, baseline characteristics, laboratory parameters and
treatment modalities did not have any significant impact on the incidence ratio of a second
cancer.
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Introduction
The incidence of non-Hodgkin’s lymphoma has
been increasing in most western countries.1 In 2007, an
estimated 8,000 people will have been newly diag-
nosed with non-Hodgkin’s lymphoma in Italy. Recent
advances have improved the prognosis of this disease,
and the introduction of monoclonal antibodies will
further ameliorate patients’ overall survival.2-6
Nowadays, many patients with non-Hodgkin’s lym-
phoma become long-term survivors, thus the risk of
developing a second cancer is becoming an important
concern.
Several studies,7-13 but not all,14-16 have reported an
increased overall risk of second cancer after treatment
for non-Hodgkin’s lymphoma. However, in a large
majority of the research, all the categories of non-
Hodgkin’s lymphoma were combined for analysis.
Furthermore, nearly all the studies were population-
based. Although the investigations analyzed thou-
sands of patients, they utilized cancer registry databas-
es that usually contain limited information on patients’
clinical characteristics and radiotherapy or chemother-
apy regimens. In the present study, we analyzed a
large cohort of patients with diffuse large B-cell lym-
phoma who entered clinical trials organized by the
Gruppo Italiano Studio Linfomi (GISL). The aims of this
long term follow-up study were to determine the inci-
dence of and risk factors for developing second cancer
in a homogeneous group of patients for whom clinical
characteristics as well as first line and subsequent
treatments were recorded at the times of diagnosis and
recurrence.
Design and Methods
Patients
The GISL maintains a central database located in
Modena that includes information on the treatment and
follow-up of all non-Hodgkin’s lymphoma patients
enrolled in clinical trials. Data managers at participating
centers routinely update the central GISL database every
3-6 months throughout the trials and every 6-12 months
during follow-up. Data managers fill out standardized
forms that collect information on patient’s characteris-
tics, laboratory parameters, treatments, outcome, late
toxicity, and the occurrence of second cancers. Data
managers describe the observed second cancers, which
are subsequently codified in Modena. When necessary,
additional information is requested from the investiga-
tors concerned. Eligibility criteria for inclusion in this
study were the following: (i) a histologically confirmed
diagnosis of diffuse large B-cell lymphoma that was pre-
viously untreated, (ii) data (as reported in Table 1) on
clinical characteristics, laboratory parameters, treat-
ments, outcome, and the occurrence of second cancers
available in the database, and (iii) available information
in the database for follow-ups of more than 6 months
after diagnosis. 
Between 1988 and 2003, 1387 patients with diffuse
large B-cell lymphoma were enrolled in a number of
GISL trials. Of these patients, 107 (7.7%) were excluded,
as they did not meet the eligibility criteria. Thus for the
purposes of this study, we included a total of 1280
patients with diffuse large B-cell lymphoma. The treat-
ment regimens utilized and the number of patients who
entered the clinical trials and received specific treatments
are as follows: LA0017: methylprednisolone + cyclophos-
phamide + doxorubicin + etoposide + cytarabine +
bleomycin + vincristine + methotrexate (ProMaCE-
CytaBOM) (number of patients = 24); LA0118: methyl-
prednisolone + cyclophosphamide + epidoxorubicin +
etoposide + cytarabine + bleomycin + vincristine +
methotrexate (ProMECE-CytaBOM) versus metho-
trexate + leucovorin + doxorubicin + cyclophosphamide
+ vincristine + bleomycin + prednisone (MACOP-B)
(number of patients = 176); LA0219: ProMECE-CytaBOM
versus methylprednisolone + cyclophosphamide + idaru-
bicin + etoposide + cytarabine + bleomycin + vincristine
+ methotrexate (ProMICE-CytaBOM) (number of
patients = 201); LA0320: fixed ProMECE-CytaBOM ver-
sus fixed ProMICE-CytaBOM versus flexible ProMECE-
CytaBOM versus flexible ProMICE-CytaBOM (number
of patients = 281); LA0421 pilot: sequential ProMECE-
CytaBOM (number of patients=23); LA0422: sequential
ProMECE-CytaBOM versus cyclic ProMECE-CytaBOM
(number of patients = 98); LA0523: ProMECE-CytaBOM +
rituximab (ProMECE-CytaBOM +R) (number of patients
= 142); GASTRO24: ProMECE-CytaBOM or cyclophos-
phamide + mitoxantrone + vincristine + prednisone
(CNOP) (number of patients = 58); PELOC (ongoing
trial): ProMECE-CytaBOM + radiotherapy (number of
patients = 150); ANZINTER25: cyclophosphamide + epi-
doxorubicin + vinblastine + prednisone (mini-CEOP) ver-
sus epidoxorubicin + cyclophosphamide + etoposide +
vinblastine + bleomycin + prednisone (P-VEBEC) (num-
ber of patients = 75); ANZINTER226: cyclophosphamide
+idarubicin + etoposide + prednisone (CIEP) (number of
patients = 25); ANZINTER327: rituximab + cyclophos-
phamide + epidoxorubicin + vincristine + prednisone (R-
CHOP) versus rituximab + mini-CEOP (R-mini-CEOP)
(number of patients =27). Upon completion of
chemotherapy, involved-field radiotherapy was permit-
ted at the treating physician’s discretion to irradiate
residual masses or the sites of previous bulky or extran-
odal disease. According to study protocols, radiotherapy
consisted of 30-38 Gy. The patients’ information,
grouped by treatment modality, is reported in Table 1.
All the GISL trials complied with the requirements of
the Declaration of Helsinki and its amendments and
were conducted in accordance with Good Clinical
Practice guidelines. The protocols were approved by the
institutional review board at each participating center.
Written informed consent was obtained from all
patients. Approval for the present study was obtained
from the review board of the GISL. 
Statistical methods
Follow-up began at the end of the first treatment for
non-Hodgkin’s lymphoma and ended at the date of
death, the date of last follow-up evaluation, the date of
diagnosis of second cancer, or the end of the study
S. Sacchi et al. 
| 1336 | haematologica | 2008; 93(9)
(July 31, 2007), whichever occurred first. Follow-ups
were updated every 3-12 months. Observed cancers
were classified by site in accordance with the oncolo-
gy section of the International Classification of
Disease.28 Individuals who developed malignancies
within 6 months of the diagnosis of their diffuse large
B-cell lymphoma, who developed synchronous cancer
during chemotherapy, or whose non-Hodgkin’s lym-
phoma was not their primary cancer were excluded
from this analysis. 
The primary aims of this research were to determine
the crude rate of second neoplasm, the standardized
incidence ratio (SIR), the cumulative incidence, the
time free to second tumor (TF2T) and the risk factors
for the development of second cancer. The crude rate
is the ratio between the observed number of second
malignancies and overall person-years of follow-up,
expressed per 1000 person-years. The incidence num-
bers of second neoplasia by person-years under analy-
sis of second cancers in the study population were
compared to the incidence of malignancies in the
Italian population, utilizing age-, sex- and calendar
period-specific incidence rates, derived from the Italian
Institute of Health database.29 The SIR was calculated
from the ratio between observed and expected num-
bers of cancers; 95% confidence intervals (95% CI)
were based on the assumption that the observed num-
bers of second cancer were distributed as the Poisson
variable. Every SIR was reported with its own 95%
confidence interval.30 Absolute excess risk (AER) of
second cancer was calculated by subtracting the
expected from the observed cases and dividing by the
person-years at risk. The AER is expressed per 10,000
person-years. Heterogeneity and trend in SIR accord-
ing to demographics, baseline characteristics and treat-
ment factors were checked by the χ2 test for unequal
SIR, according to Breslow and Day.31 Cumulative inci-
dences were estimated in the competing risk model
with death from any cause considered a competing
event.32,33 The TF2T was measured from the end of the
first treatment to the last follow-up or date of diagno-
sis of the second tumor and was calculated with a
Kaplan-Meier estimate. 
A proportional hazards model that adjusted for com-
peting causes of mortality, Fine and Gray’s regression,34
was used to determine the clinical factors associated
with the TF2T in univariate and multivariate analyses.
Examination of the Schoenfeld residuals and TF2T for
each covariate was performed to assess the subdistrib-
ution proportional hazards assumption in the regres-
sions for all models considered. For all of the fitted
models, the Schoenfeld residuals were between -1.0
and 1.0. No apparent abnormal patterns were found
against the assumptions of Fine and Gray’s regression.
R version 2.3.135 was used for all calculations pertain-
ing to the Fine and Gray's regression and cumulative
incidence probability estimates of TF2T. The Stata
8.2/SE package36 was used for all remaining statistical
analyses.
As the present study is a retrospective analysis, we
did not plan a sample size. For all tests, a two-sided p
value <0.05 was considered to demonstrate a moder-
ate strength of evidence against the null hypothesis.
This level of probability is helpful for providing clini-
cally useful advice. 
The International Prognostic Index (IPI) score, which
takes into account elevated lactate dehydrogenase lev-
els, clinical stage III-IV disease, age >60 years, more
than one extranodal site of disease, and Eastern
Cooperative Oncology Group (ECOG) score ≥ 2, was
calculated for 95% of the patients in the cohort.37
Results
Patients’ characteristics
Between 1988 and 2003, 1387 patients with diffuse
large B-cell lymphoma were enrolled in a number of
GISL trials. Of these patients, 107 (7.7%) were exclud-
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Table 1. Descriptive characteristics and treatments utilized in the
1280 patients with aggressive lymphoma.
Characteristics N. of patients % of patients Person-years at risk 
1280 100 6316
Age at diagnosis (years)
14-44 301 24 1671
45-59 424 33 2275
60-69 382 30 1835
70-86 173 14 534
Gender
Male 688 54 3436
IPI scorea
0-1 604 50 3591
2 329 27 1542
3-5 281 23 899
Bulky disease
Yes 318 25 1390
B-Symptoms
Yes 352 28 1510
Extranodal sites
> 1 267 21 1043
Chemotherapy regimens
PCB-epidoxorubicin 724 57 3760
PCB-idarubicin 222 17 1126
PCB-sequential 150 12 842
CHOP or CHOP-like 184 14 588
Radiotherapy - Involved Field
Yes 367 29 1972
More than one line of treatment
>1 306 24 1179
>2 116 9 456
Follow-up
5 years or less 751 1318
more than 5 years 529 4998
more than 10 years 206 2586
aMissing for 66 of 1280 (5.2%). Because of rounding, percentages may not total
100. PCB-epidoxorubicin: ProMECE-CytaBOM: (methylprednisolone,
cyclophosphamide, epidoxorubicin -or doxorubicin-, etoposide, cytarabine,
bleomycin, vincristine, methotrexate); PCB-idarubicin: ProMICE-CytaBOM
(methylprednisolone, cyclophosphamide, idarubicin, etoposide, cytarabine,
bleomycin, vincristine, methotrexate); PCB-Sequential: sequential ProMECE
instead of the classical cycling regimen; CHOP: cyclophosphamide, doxorubicin
vincristine, prednisolone.
ed: 57 did not complete the planned chemotherapy
and were lost immediately during the follow-up peri-
od, 10 were misdiagnosed, and 40 lacked sufficient
data.
A total of 1280 patients with diffuse large B-cell lym-
phoma met the defined eligibility criteria and were
included in this analysis. The overall quality of the
case record forms was good; only for 5% of the forms
was the IPI score unable to be calculated. The overall
survival rates at 5, 10 and 15 years were 60%, 52% and
46%, respectively, with a median follow-up of 51
months (range 2-213 months) for all patients and 89
months for living patients. The number of patients and
follow-up times comprised 6316 person-years of risk
for a second tumor. The median age at diagnosis was
58 years (range, 14-86), and 54% (n=688) of the
patients were male. All patients were treated with
chemotherapy, either alone (71%) or in combination
with radiotherapy (29%). The patients’ characteristics
and treatments are summarized in Table 1. 
Second malignancies
During the follow-up, 48 patients (3.8%, crude rate
7.6 per 1000 person-years) developed a second cancer. A
total of 568 patients died, 48 were lost during the fol-
low-up period, and the remaining 664 patients (18 with
a second cancer) survived to the end of the study period.
The most common causes of death were progressive dis-
ease (75%), infections (5%), second cancer (4%), treat-
ment-related toxicity (4%) and cardiopathy (1%). No
patients developed a third cancer during the follow-up
period. Eight of the 48 patients with second cancers
developed myelodysplastic syndrome (MDS)/acute
myeloid leukemia (AML) (5 and 3 cases, respectively), 5
developed other hematologic malignancies, and 35
developed solid tumors, including colorectal carcinoma
(n=8), lung cancer (n=8), and other types of cancer
(n=19) (Table 2).
We did not observe any cases of second non-
Hodgkin’s lymphoma. However, biopsies with histolog-
ical examination were usually not performed in relapsed
cases, and further occurrences were commonly consid-
ered relapses. Thus, the incidence of Hodgkin’s lym-
phoma and new non-Hodgkin’s lymphoma could be
underestimated. Fourteen of the 48 second malignancies
occurred after additional treatments for progressive or
recurrent disease. The median time from diagnosis of
diffuse large B-cell lymphoma to diagnosis of a solid
tumor was 71 months (range, 13-176 months), and that
to diagnosis of MDS/AML was 43 months (range, 30-
127 months).
Incidence of second malignancies 
The overall risk of second cancer in patients with
diffuse large B-cell lymphoma was similar to that in
the general Italian population (SIR: 1.1; 95% CI: 0.8-
1.5). The analysis of SIR by cancer type showed that
incidences were increased for lung cancer (SIR: 1.6;
95% CI: 0.7-3.2), colorectal cancer (SIR: 1.3; 95% CI:
0.6-2.5) and prostate cancer (SIR: 1.6; 95% CI: 0.4-4.1),
and decreased for breast cancer (SIR: 0.5; 95% CI: 0.1-
1.6). However, differences compared to the Italian gen-
eral population were not statistically significant. We
did not calculate the SIR of MDS/AML and bladder
cancer, as the incidence rates of these malignancies are
not reported by the Italian Institute of Health.
Furthermore, we did not evaluate the SIR for cancers
for which fewer than three cases were diagnosed in
our cohort. Gender, IPI score, chemotherapy regimens,
radiotherapy, number of chemotherapy lines and time
of first treatment did not have any significant impact
on the SIR of developing a second cancer (Table 3).
The risk of second malignancies in relation to age at
diagnosis of second cancer is shown in Table 4. An
increased and statistically significant risk of second
cancer was observed in the cohort groups 20-39 and
40-59 years of age. 
Kaplan-Meir estimates of cumulative incidence of
second cancer including MDS/AML, calculated as 1.0
minus Kaplan-Meier estimate of TF2T, were 3.4%,
7.6%, and 14% at 5, 10, and 15 years, respectively.
After correction in a competing-risk model by Grays’
method, the cumulative incidences were reduced to
2.3, 4.7, and 8.2, respectively (Figure 1A). Considered
separately, the cumulative incidence for solid tumors
was 1.5, 3.3, and 6.8, and for hematologic malignan-
cies 0.8, 1.4, and 1.4 at 5, 10, and 15 years, respective-
ly (Figure 1B). We did not observe any plateau in the
solid tumor curve, while the curve of hematologic
malignancies stopped increasing after 10 years.
Risk factors for developing second malignancies
In a univariate Gray-Fine regression analysis, the only
factor that had a significant negative impact on TF2T was
age >60 years at first treatment. This result was con-
firmed in a multivariate analysis. Factors that did not sig-
nificantly influence TF2T included gender, IPI score, type
of chemotherapy, radiotherapy and number of
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Table 2. Cases and sites of second primary cancer.
Second cancer ICD-9 N. of % of Person-years
code patients patients at risk
MDS/AML 238.72-238.73- 8 17 40
205-208
Lung 162 8 17 43
Digestive traet 153-154 8 17 42
Prostate 185 4 8 30
Breast 174 3 6 18
Bladder 188 3 6 22
Stomach 151 2 2 9
Skin 173 2 4 9
Vulva 184 2 4 18
Hodgkin’s lymphoma 201 2 4 3
Acute lymphoblastic leukemia 204.1 2 4 3
Multiple myeloma 203 1 2 2
Brain 191-192 1 2 3
Ovary 183 1 2 3
Testicle 186 1 2 10
Total n. of tumors − 48 100 6316
No second tumors − 1232 96.2 6061
ICD-9: International Classification of Diseases 9th Edition.
http://www.cdc.gov/nchs/icd9.htm. Because of rounding, percentages may not
total 100.  
chemotherapy lines (Table 5). Having received more than
two lines of chemotherapy plus radiotherapy did not
have a negative impact on TF2T. However, this conclu-
sion was drawn from the observation of a cohort of only
80 patients (data not shown). In a separate analysis, no vari-
ables, including age, sex and advanced Ann Arbor stage
disease, appeared to be associated with the development
of MDS/AML. Lung cancer was most frequent in males,
but the association was not statistically significant.
Discussion
Because of successful treatment, a large number of
patients with Hodgkin’s lymphoma become long-term
survivors, and thus remain at life-long risk of late
sequelae. Better treatments2-6 have improved the life
expectancy of patients with non-Hodgkin’s lym-
phoma, and the risk of late treatment effects is now
becoming an important concern. Despite a few reports
to the contrary,14-16 the majority of published studies
have shown that non-Hodgkin’s lymphoma patients
are at a greater risk of second malignancies.7-13
These conflicting results could be explained in part by
the different epidemiological and statistical methods uti-
lized for evaluating the incidence of second cancers.38
Two commonly used epidemiological designs are cohort
and case-control studies. Among cohort studies, sources
of information include population-based cancer reg-
istries and clinical trial databases. The major disadvan-
tage of population-based studies is that treatment data
are limited, when present. However, these studies usu-
ally include a large number of patients, and thus even a
small risk can be detected. In contrast, clinical trial data-
bases often include a relatively low number of patients
thus not enabling the assessment of small risks.
However, these databases contain precise information
Second cancer after treatment for DLBCL
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Table 3. Standardized incidence risk (SIR) and absolute excess
risk (AER per 10,000 person-years) of second cancer analyzed
according to demographics, baseline characteristics and treat-
ments (41 cases out of 48).*
Factor Observed Expected SIR (95%CI) AER p value**
Gender
Female 16 16.0 1.00 (0.57-1.62) 0.00 0.618
Male 25 21.4 1.17 (0.76-1.73) +10.1
IPI score
0-1 20 17.6 1.13 (0.69-1.75) +6.60 0.959
2-5 21 18.2 1.15 (0.71-1.76) +10.8
Chemotherapy 
PCB-epidoxorubicin 24 19.7 1.22 (0.78-1.81) +11.1 0.610
PCB-idarubicin 7 6.2 1.12 (0.45-2.31) +6.87
PCB-sequential 6 4.8 1.24 (0.46-2.70) +13.8
CHOP or CHOP-like 4 6.6 0.60 (0.16-1.55) -42.1
RT-IF
No 32 27.6 1.16 (0.79-1.63) +9.72 0.549
Yes 9 9.7 0.92 (0.42-1.75) -3.52
N. of chemotherapies lines
1 29 27.2 1.06 (0.71-1.53) +3.73 0.804
2 7 6.7 1.04 (0.42-2.15) +2.46
3 5 3.4 1.45 (0.47-3.39) +34.2
Years of first treatment 
1988-91 10 11.6 0.86 (0.41-1.59) -7.93 0.678
1992-95 17 12.5 1.36 (0.79-2.18) +20.2
1996-99 9 7.9 1.14 (0.52-2.15) +8.35
2000-03 5 5.4 0.93 (0.30-2.16) -4.18
*Five MDS and two skin cancers cases were excluded. **Chi-square test for
unequal SIR 315. RT-IF: involved field radiotherapy; IPI: International
Prognostic Index for aggressive lymphoma; PCB-epidoxorubicin: ProMECE-
CytaBOM: (methylprednisolone, cyclophosphamide, epidoxorubicin -or doxoru-
bicin-, etoposide, cytarabine, bleomycin, vincristine, methotrexate); PCB-idaru-
bicin: ProMICE-CytaBOM (methylprednisolone, cyclophosphamide, idarubicin,
etoposide, cytarabine, bleomycin, vincristine, methotrexate); PCB-Sequential:
sequential ProMECE instead of the classical cycling regimen; CHOP: cyclophos-
phamide, doxorubicin vincristine, prednisolone.
Table 4. Standardized incidence risk (SIR) and absolute excess
risk (AER per 10,000 person-years) of second cancer (41 cases
out of 48)* related to age-, and calendar period- specific incidence
derived from the ISS** database, by ICD-9 code from 140 to 208. 
Cohort Observed Expected SIR 95% C.I. AER
Age failures failures
20–39 2 0.09 23.0 5.76-92 +20.6
40–59 6 1.37 4.39 1.97-9.78 +18.6
60–64 5 5.69 0.88 0.37-2.11 -7.49
65–69 11 9.51 1.16 0.64-2.09 +15.2
70–74 11 10.4 1.06 0.58-1.91 +8.16
75–79 3 6.84 0.44 0.14-1.36 -102
80+ 3 3.42 0.88 0.28-2.72 -25.6
Total 41 37.3 1.10 0.81-1.49 +5.70
*Five MDS and two skin cancers cases were excluded; **ISS: Istituto Superiore
di Sanità (Italian National Institute of Health).  
Table 5. Gray-Fine univariate regression, accounting for competing
risk of death, for demographics, baseline characteristics and
treatments of the patients at diagnosis of DLBCL. 
Covariate Coef. SE HR p
Age >60 years old 0.783 0.295 2.19 0.008
Gender, Male 0.260 0.294 1.30 0.38
LDH > UNL -0.007 0.300 0.99 0.98
Stage III-IV -0.218 0.285 0.44 0.80
PS 2-4 0.061 0.521 1.06 0.91
Extra nodal sites >1 -0.196 0.339 0.82 0.56
IPI 3-5 0.070 0.287 1.07 0.81
RT-IF Yes -0.314 0.354 0.73 0.37
Chemotherapy
PCB epidoxorubicin 1.00
PCB idarubicin -0.293 0.408 0.75 0.47
PCB sequential -0.080 0.432 0.92 0.85
CHOP or CHOP-like 0.095 0.434 1.10 0.83
N. of lines of chemotherapy
1 line 1.00
2 lines -0.455 0.384 0.63 0.24
3 lines 0.035 0.463 1.04 0.94
LDH: lactate dehydrogenase; UNL :institutional upper normal limit; Stage: Ann
Arbor staging; PS: performance status; IPI: International Prognostic Index for
aggressive lymphoma; RT-IF: involved field radiotherapy. PCB-epidoxorubicin:
ProMECE-CytaBOM: (methylprednisolone, cyclophosphamide, epidoxorubicin -
or doxorubicin-, etoposide, cytarabine, bleomycin, vincristine, methotrexate);
PCB-idarubicin: ProMICE-CytaBOM (methylprednisolone, cyclophosphamide,
idarubicin, etoposide, cytarabine, bleomycin, vincristine, methotrexate); PCB-
Sequential: sequential ProMECE instead of the classical cycling regimen; CHOP:
cyclophosphamide, doxorubicin vincristine, prednisolone.
on clinical characteristics, treatments and occasionally
data on long-term follow-up. The methodology and sta-
tistical approach utilized for estimation of second malig-
nancies is also important. For a disease such as diffuse
large B-cell lymphoma, in which early deaths are fre-
quent due to recurrent or refractory disease, any cumu-
lative incidence evaluated by the Kaplan-Meier method
will result in an overestimated percentage of second
malignancies. Thus, correction by a competing risk
model is necessary. Furthermore, as time, sex, environ-
mental and genetic factors influence and modify the
incidence of cancer, person-years analysis per geograph-
ical region, age-, sex- and calendar period-specific inci-
dence ratios are needed for optimal evaluation of the SIR
and AER. In our study, the incidence of second malig-
nancy was analyzed in a cohort of 1280 patients treated
for diffuse large B-cell lymphoma. The source of the
data was GISL, which maintains a database on treat-
ment and follow-up of all patients with non-Hodgkin’s
lymphoma enrolled in clinical trials. Although per-
formed in a homogeneous and relatively large cohort of
patient with a long-term follow-up, the results of this
research should be interpreted cautiously due to the ret-
rospective design of the study. Furthermore, as data
managers at participating centers were not urged to
specifically report second cancers, our results could
slightly underestimate the risk of such cancer. Our
research, exclusively examining patients treated for dif-
fuse large B-cell lymphoma could only be conclusively
compared with a small number of other studies15,16 that
explored the same topic, and reports of those studies
revealed partially similar findings. 
Our results showed that the overall incidence of sec-
ond malignancies is not significantly increased.
However, comparing our diffuse large B-cell lymphoma
cohort with the general Italian population, the SIR of
cancer was found to be increased in the age groups 20-
39 and 40-59 years old. The incidence in patients aged
over 59 years old matched that in the Italian general
population. Thus, the risk of second cancer was clearly
age-related: in young patients a strongly increased risk
was observed while the incidence in patients aged more
than 59 years, when first treated for non-Hodgkin’s lym-
phoma, matched the incidence in the general popula-
tion. We observed an increased cancer-specific risk for
lung, colorectal and prostate cancer, and a decreased risk
for breast cancer, but the differences from the Italian
general population were not statistically significant. The
three female patients who developed breast cancer were
over 58 years of age; no cases were observed in younger
women, likely due to the hormonal changes induced by
chemotherapy.39 Baseline characteristics and the differ-
ent treatment modalities did not have an influence on
the SIR. In particular, having received radiotherapy after
chemotherapy or more than one line of chemotherapy
did not have a negative impact on SIR. One possible
explanation for these findings could be the use of
involved field radiotherapy with a maximum dose of 3.8
Gy or too short a follow-up period. Furthermore, it is
possible that relapsed or refractory patients who
received salvage treatments died before living long
enough to develop a second cancer. Some authors
observed an increased SIR for AML,10,12 others for
AML/MDS15, while others did not find any increase for
AML and did not evaluate the SIR for MDS.16 As we
could not evaluate the SIR for AML and MDS for tech-
nical reasons, we calculated the crude rate in our cohort
and compared this with crude rates evaluated in other
research. We observed a crude rate for MDS/AML
together of 1.3 (95% CI, 0.5-2.5) which is an intermedi-
ate value between the 1.1 (95% CI, 0.6-2.5) and 2.0
(95% CI, 0.9-3.7) calculated in other reports that
showed15 or failed to show16 an increased risk for
AML/MDS or AML, respectively. The cumulative inci-
dence of second tumors was similar to those reported by
others.15,16 However, while we did not observe any
plateau in the curve of solid tumors, the cumulative inci-
dence of hematologic malignancies stopped increasing
S. Sacchi et al. 
| 1340 | haematologica | 2008; 93(9)
Figure 1. (A) Cumulative inci-
dence of second cancer in the
Kaplan-Meier (CI - KM) estima-
tion compared to the cumula-
tive incidence according to
Gray (CI - Gray). (B) Cumulative
incidence of second cancer
according to Gray, divided into
solid and hematologic malig-
nancies. 
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after 10 years. The only factor with a negative impact on
the probability of remaining free of second cancers was
age over 60 years old at diagnosis of diffuse large B-cell
lymphoma; the other baseline characteristics and treat-
ment did not have any significant influence. 
In conclusion, data from our homogeneous GISL
cohort of patients treated for diffuse large B-cell lym-
phoma showed that it is principally young patients who
have an increased risk of second cancers, while older
patients are at the same risk as the normal Italian popu-
lation. Our cohort had a median age of 58 years, and this
is likely one of the reasons that the overall risk did not
appear elevated with respect to the entire cohort.
However, the cumulative incidence of solid tumors is
still increasing after 12-15 years, and a longer follow-up
could be necessary to confirm that the risk in our cohort
is the same as that observed in the normal population. 
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